[go: up one dir, main page]

IN2012DN03128A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03128A
IN2012DN03128A IN3128DEN2012A IN2012DN03128A IN 2012DN03128 A IN2012DN03128 A IN 2012DN03128A IN 3128DEN2012 A IN3128DEN2012 A IN 3128DEN2012A IN 2012DN03128 A IN2012DN03128 A IN 2012DN03128A
Authority
IN
India
Prior art keywords
compositions
eye
active ingredient
treatment
group
Prior art date
Application number
Inventor
Bastian Theisinger
Sonja Theisinger
Bernhard Gunther
Original Assignee
Novaliq Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41731659&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN03128(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novaliq Gmbh filed Critical Novaliq Gmbh
Publication of IN2012DN03128A publication Critical patent/IN2012DN03128A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention provides novel pharmaceutical compositions for the treatment of keratoconjunctivitis sicca comprising liquid vehicles which include one or more semifluorinated alkanes. The compositions incorporate an active ingredient selected from the group of macrolide immunosuppressants. They can be administered topically into the eye. The invention further provides kits comprising such compositions.
IN3128DEN2012 2009-12-14 2010-12-13 IN2012DN03128A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09015423A EP2335735A1 (en) 2009-12-14 2009-12-14 Pharmaceutical composition for treatment of dry eye syndrome
PCT/EP2010/069495 WO2011073134A1 (en) 2009-12-14 2010-12-13 Pharmaceutical composition for treatment of dry eye syndrome

Publications (1)

Publication Number Publication Date
IN2012DN03128A true IN2012DN03128A (en) 2015-09-18

Family

ID=41731659

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3128DEN2012 IN2012DN03128A (en) 2009-12-14 2010-12-13

Country Status (15)

Country Link
US (1) US8614178B2 (en)
EP (2) EP2335735A1 (en)
JP (5) JP5663595B2 (en)
KR (2) KR101722039B1 (en)
CN (1) CN102652022B (en)
AU (1) AU2010333039B2 (en)
BR (3) BR122020020872B1 (en)
CA (2) CA2941956C (en)
DK (1) DK2512515T3 (en)
ES (1) ES2449308T3 (en)
IN (1) IN2012DN03128A (en)
MX (1) MX2012006720A (en)
PL (1) PL2512515T3 (en)
PT (1) PT2512515E (en)
WO (1) WO2011073134A1 (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2921527T3 (en) 2009-06-03 2022-08-29 Forsight Vision5 Inc Anterior segment drug delivery
KR101656121B1 (en) 2010-03-17 2016-09-08 노바리크 게엠베하 Pharmaceutical composition for treatment of increased intraocular pressure
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
EP2714008B1 (en) 2011-05-25 2016-12-14 Novaliq GmbH Pharmaceutical composition for administration to nails
PT2714010T (en) 2011-05-25 2017-05-05 Novaliq Gmbh Topical pharmaceutical composition based on semifluorinated alkanes
CA2862974C (en) 2012-01-23 2021-11-16 Novaliq Gmbh Stabilised protein compositions based on semifluorinated alkanes
CN113679697A (en) * 2012-09-12 2021-11-23 诺瓦利克有限责任公司 Compositions comprising mixtures of semifluorinated alkanes
CA2883003C (en) * 2012-09-12 2021-11-16 Novaliq Gmbh Semifluorinated alkane compositions
EP2708228B1 (en) 2012-09-12 2018-05-16 Novaliq GmbH Eye wash compositions
EP2730291A1 (en) * 2012-11-09 2014-05-14 Fluoron Gmbh Internal Tamponade Composition
CA2899206C (en) 2013-01-24 2019-07-09 Transderm, Inc. Compositions for transdermal delivery of mtor inhibitors
JP6304475B2 (en) * 2013-01-31 2018-04-04 ロート製薬株式会社 Eye drops
CA2905247C (en) 2013-03-13 2021-02-16 Santen Pharmaceutical Co., Ltd. Therapeutic agent for meibomian gland dysfunction
ES2687094T3 (en) 2013-07-23 2018-10-23 Novaliq Gmbh Stabilized antibody compositions
US20160243291A1 (en) * 2013-10-15 2016-08-25 Forsight Vision5, Inc. Formulations and Methods for Increasing or Reducing Mucus
US11324800B2 (en) 2015-01-15 2022-05-10 Wellspring Ophthalmics, Inc. Aqueous suspensions of cyclosporin
US20200237859A1 (en) 2019-01-25 2020-07-30 Newport Research, Inc. Aqueous suspensions of cyclosporin
WO2016168141A1 (en) 2015-04-13 2016-10-20 Forsight Vision5, Inc. Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent
US11013403B2 (en) * 2015-09-29 2021-05-25 The Regents Of The University Of California Methods of diagnosing diseases of mucosal surfaces
DK3722274T3 (en) * 2015-09-30 2023-09-11 Novaliq Gmbh 2-PERFLUORBUTYLPENTANE FOR OPHTHALMIC ADMINISTRATION
DE202016008738U1 (en) 2015-09-30 2019-04-09 Novaliq Gmbh Semifluorinated compounds and their compositions
ES2763121T3 (en) 2016-06-23 2020-05-27 Novaliq Gmbh Topical administration method
CA3036297C (en) * 2016-09-22 2023-09-05 Novaliq Gmbh Pharmaceutical compositions for use in the therapy of blepharitis
US10813976B2 (en) 2016-09-23 2020-10-27 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
AU2017333420A1 (en) * 2016-09-28 2019-04-04 Novaliq Gmbh Compositions comprising a cannabinoid receptor binding ligand
AU2017380769B2 (en) * 2016-12-22 2023-12-21 Novaliq Gmbh Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases
ES2965883T3 (en) * 2016-12-23 2024-04-17 Novaliq Gmbh Ophthalmic composition for the treatment of dry eye disease
IL302385B2 (en) 2017-01-06 2024-06-01 Palvella Therapeutics Inc Anhydrous compositions of mtor inhibitors and methods of use
WO2018193093A1 (en) * 2017-04-21 2018-10-25 Novaliq Gmbh Iodine compositions
US10717691B2 (en) 2017-05-05 2020-07-21 Novaliq Gmbh Process for the production of semifluorinated alkanes
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
CA3076776A1 (en) 2017-09-27 2019-04-04 Novaliq Gmbh Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
CN120022260A (en) 2017-10-04 2025-05-23 诺瓦利克有限责任公司 Ophthalmic compositions comprising F6H8
WO2019166631A1 (en) 2018-03-02 2019-09-06 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
EP3784246A1 (en) 2018-04-27 2021-03-03 Novaliq GmbH Ophthalmic compositions comprising tafluprost for the treatment of glaucoma
JP2021530463A (en) 2018-07-02 2021-11-11 パルヴェラ セラピューティクス、インク． Anhydrous composition of mTOR inhibitor and how to use it
SG11202102818YA (en) 2018-09-22 2021-04-29 Novaliq Gmbh Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness
JP7360452B2 (en) 2018-09-27 2023-10-12 ダーマリック セラピューティクス， インコーポレーテッド Lipid barrier repair
AU2019358249B2 (en) 2018-10-12 2024-02-22 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
WO2020152046A1 (en) * 2019-01-21 2020-07-30 Novaliq Gmbh Pharmaceutical composition for the treatment of ocular neovascularisation
EP3923907B1 (en) 2019-02-13 2024-09-25 Novaliq GmbH Compositions and methods for the treatment of ocular neovascularization
US20220226426A1 (en) 2019-05-24 2022-07-21 Novaliq Gmbh Ophthalmic composition for the treatment of ocular allergy
KR20220058577A (en) 2019-09-06 2022-05-09 노바리크 게엠베하 Ophthalmic composition for the treatment of uveitis
WO2021048803A1 (en) 2019-09-13 2021-03-18 Minas Coroneo Eye drop dispenser
WO2021191273A1 (en) 2020-03-24 2021-09-30 Hovione Scientia Limited Compositions for use in treating meibomian gland dysfunction
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
IL322635A (en) * 2023-02-13 2025-10-01 Novaliq Gmbh Ophthalmic composition for ocular surgery preparation in patients with ocular surface disease
AU2023270196B2 (en) * 2023-11-20 2025-06-26 Dyer, Gordon Wayne DR Method of Arthropod Egress

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839342A (en) 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
DE3851152T2 (en) 1987-09-03 1995-01-26 Univ Georgia CYCLOSPORINE EYE PRODUCTS.
US5874481A (en) * 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
DE19536504C2 (en) 1995-09-29 1999-09-23 H Meinert Use of fluorinated alkanes
DE19861012A1 (en) * 1998-03-18 1999-09-30 Pharm Pur Gmbh Ophthalmological use of fluorocarbon with low dissolved oxygen content, e.g. for treating ischemic retinal disease
CZ20013769A3 (en) * 1999-04-30 2002-03-13 Sucampo Ag Agent for treating dry eye
DE19938668B4 (en) * 1999-08-14 2006-01-26 Bausch & Lomb Inc. Artificial tears
US20030018044A1 (en) * 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
ES2387619T3 (en) * 2004-04-19 2012-09-27 Centre National De La Recherche Scientifique (Cnrs) Pulmonary Surfactant Supplements
US20050288196A1 (en) * 2004-06-08 2005-12-29 Ocularis Pharma, Inc. Silicone polymer contact lens compositions and methods of use
DE102007055046A1 (en) * 2007-11-19 2009-05-28 Fluoron Gmbh infusion
DK2110126T3 (en) 2008-04-18 2012-02-27 Novaliq Gmbh Inhalation and instillation use of semifluorinated alkanes as active ingredient carriers within the intrapulmonary range

Also Published As

Publication number Publication date
BR112012014190A2 (en) 2016-05-31
EP2512515B1 (en) 2013-12-25
JP2013513586A (en) 2013-04-22
CA2941956C (en) 2018-09-04
JP6397472B2 (en) 2018-09-26
BR122020020872B1 (en) 2021-09-08
CA2776860A1 (en) 2011-06-23
JP2019006803A (en) 2019-01-17
EP2335735A1 (en) 2011-06-22
MX2012006720A (en) 2012-07-30
KR20120115977A (en) 2012-10-19
ES2449308T3 (en) 2014-03-19
WO2011073134A1 (en) 2011-06-23
CA2941956A1 (en) 2011-06-23
CN102652022A (en) 2012-08-29
AU2010333039B2 (en) 2014-08-28
KR101652714B1 (en) 2016-09-01
BR112012014190B8 (en) 2021-05-25
KR20160105533A (en) 2016-09-06
US8614178B2 (en) 2013-12-24
JP6731039B2 (en) 2020-07-29
JP2019070003A (en) 2019-05-09
BR122017018955B1 (en) 2022-03-08
US20120244177A1 (en) 2012-09-27
JP2015028064A (en) 2015-02-12
BR112012014190B1 (en) 2021-03-02
AU2010333039A1 (en) 2012-07-12
CA2776860C (en) 2016-10-25
PT2512515E (en) 2014-03-04
EP2512515A1 (en) 2012-10-24
CN102652022B (en) 2014-12-17
PL2512515T3 (en) 2014-05-30
JP5663595B2 (en) 2015-02-04
JP6096731B2 (en) 2017-03-15
KR101722039B1 (en) 2017-03-31
DK2512515T3 (en) 2014-03-10
JP2017078086A (en) 2017-04-27
HK1172269A1 (en) 2013-04-19

Similar Documents

Publication Publication Date Title
IN2012DN03128A (en)
MX389597B (en) Pyridopyrimdinone cdk2/4/6 inhibitors
WO2015106128A3 (en) Rnai agents modified at the 4'-c-position
MY175800A (en) Combination treatment of cancer
EP4342540A3 (en) Substituted heterocyclyl derivatives as cdk inhibitors
WO2012047587A3 (en) Mdm2 inhibitors for treatment of ocular conditions
WO2015070224A3 (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
MX2015010971A (en) Novel pyrazole derivative.
EP4292662A3 (en) Substituted indole mcl-1 inhibitors
WO2011113802A3 (en) Imidazopyridine and purine compounds, compositions and methods of use
EA033343B1 (en) Compounds inhibiting rip2 kinase, pharmaceutical composition based thereon and use thereof for the treatment of diseases mediated by rip2 kinase
MX2016011468A (en) Human plasma kallikrein inhibitors.
MX2013012776A (en) Amino-pyridine-containing spleen tyrosine kinase (syk) inhibitors.
BR112014000792A2 (en) Piperidinyl Compounds for Use as Tanquirase Inhibitors
EP4342537A3 (en) Semifluorinated alkane compositions
CL2012001714A1 (en) Compounds derived from pyrrole [3,4-b] pyridin-5-one, inhibitors of pi3k; pharmaceutical composition comprising them; and use for the treatment of diseases such as Alzheimer's, epilepsy, multiple sclerosis, Parkinson's, among others.
WO2012027065A3 (en) Combination therapy for treatment of disease
EP4414376A3 (en) Novel depsipeptide and uses thereof
CO2019011877A2 (en) New bicyclic pyrazole derivatives
EP3216798A3 (en) Ketolide compounds
MX2012013606A (en) Tamarind seed polysaccharide for use in the treatment of microbial infections.
EP4403552A3 (en) C-terminal hsp90-inhibitors
PH12013500644A1 (en) Co-crystals and salts of ccr3-inhibitors
CL2012003521A1 (en) Piperidino derivative (r) -n - ((r) -1 - ((3s-4s) -4- (4-chlorophenyl) -3,4-dihydroxy-3-methylpiperidin-1-yl) -3-methyl-1 -oxobutan-2-yl) -3,3-difluorocyclopentanecarboxamide, chemokine receptor modulator; pharmaceutical composition; and use of the compound and its composition in inflammatory and autoimmune diseases, among others.
MX2024010625A (en) Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof.